SV investment has resulted in the approval of 24 novel therapeutics
SV News
12 January 2021Portfolio NewsBoehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
6 January 2021Portfolio NewsRibometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics- 16 December 2020Portfolio NewsEnara Bio adds further world‐class cell therapy and immuno‐oncology expertise to Senior Management Team and Scientific Advisory Board
- 9 December 2020Portfolio NewsEnara Bio relocates to The Oxford Science Park's newest facility to expand R&D capabilities in the search for novel cancer immunotherapies
3 December 2020Portfolio NewsMerck KGaA and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology- 23 November 2020Portfolio NewsCatamaran Bio Launches with $42 Million Financing to Develop Off-the-Shelf CAR-NK Cell Therapies to Treat Solid Tumors
- 23 November 2020Portfolio NewsThe Boston Globe Names Deciphera a Top Place to Work for 2020
- 18 November 2020Portfolio NewsPionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314
- 18 November 2020Portfolio NewsSutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
17 November 2020Portfolio NewsAVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline
10 November 2020Portfolio NewsXilio Therapeutics to Present Data on Tumor-Selective Immunotherapies at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
10 November 2020SV NewsKate Bingham writes the foreword for Movers and Shakers in BioBusiness 2020
